[Stroke, platelet activating factor and receptor antagonists]

Zhongguo Zhong Yao Za Zhi. 2017 Dec;42(24):4750-4755. doi: 10.19540/j.cnki.cjcmm.2017.0212.
[Article in Chinese]

Abstract

Stroke is an acute cerebrovascular disease with high morbidity, disability and mortality. The prevention and treatment conditions for stroke is severe all over the world. Antiplatelet aggregation is an effective treatment. Platelet activation factor (PAF) is another important medium in mediating platelet aggregation, which plays an important role in the pathogenesis of stroke. In recent years, PAF receptor antagonists have attracted international attention in the field of stroke prevention and treatment. In this review, we would summarize the classification, mechanism and drug characteristics of PAF receptor antagonists in order to provide the valuable guidance and direction for clinical medicine and research.

Keywords: antiplatelet drug; platelet activating factor; receptor antagonist; stroke; thrombus.

Publication types

  • Review

MeSH terms

  • Cerebrovascular Disorders / drug therapy
  • Cerebrovascular Disorders / prevention & control*
  • Humans
  • Platelet Activating Factor / antagonists & inhibitors*
  • Platelet Aggregation
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Receptors, G-Protein-Coupled
  • Stroke / drug therapy
  • Stroke / prevention & control*

Substances

  • Platelet Activating Factor
  • Platelet Aggregation Inhibitors
  • Receptors, G-Protein-Coupled